SearchDictionaryMobileLogin

Rachel Schiff Selected Research

Estrogens (Estrogen)

02/2008Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
12/2007The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm.
12/2006Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
08/2006Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
11/2005Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
09/2005Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
06/2005Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations.
04/2005Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
01/2005Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
06/2004Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
12/2003Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
09/2003Estrogen-mediated down-regulation of E-cadherin in breast cancer cells.
03/2003Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
01/2003Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Articles by Research Topic

Disease

22Breast Neoplasms (Breast Cancer)
09/2008 - 10/2002
5Neoplasms (Cancer)
08/2006 - 05/2003

Drug/Important Bio-Agent (IBA)

14Estrogens (Estrogen)FDA Link
02/2008 - 01/2003
6TamoxifenFDA LinkGeneric
02/2008 - 03/2003
2Epidermal Growth Factor Receptor (EGF Receptor)IBA
09/2007 - 05/2007
2trastuzumab (Herceptin)FDA Link
09/2007 - 04/2005
2Progesterone Receptors (Progesterone Receptor)IBA
10/2005 - 09/2005
1fulvestrant (Faslodex)FDA Link
08/2006
1Somatotropin Receptors (Growth Hormone Receptor)IBA
08/2006
1pegvisomantFDA LinkGeneric
08/2006
1Estrogen Receptor Modulators (Antiestrogen)IBA
04/2005
1Protein Kinases (Protein Kinase)IBA
04/2005
1Estrogen Receptor alphaIBA
01/2005
1HormonesIBA
01/2005
1Cadherins (E-Cadherin)IBA
09/2003
1Estrogen Receptor betaIBA
05/2003
1Aromatase InhibitorsIBA
01/2003
1Selective Estrogen Receptor Modulators (SERM)IBA
01/2003
1Transcription Factors (Transcription Factor)IBA
10/2002
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
10/2002

Therapy/Procedure

3Heterologous Transplantation (Xenotransplantation)
09/2008 - 08/2006